neuroprotection

Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...

JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...

October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...